Clinical trial NCT03492346: Limb Girdle Muscular Dystrophy Type 2E Recruitment Study
Official title: Limb Girdle Muscular Dystrophy Type 2E Recruitment Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Limb-Girdle Muscular Dystrophy, Type 2E
Keywords: LGMD2E
Limb Girdle Muscular Dystrophy
sarcoglycanopathy
β -sarcoglycan
Natural History
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
Collaborators: name: Myonexus Therapeutics
First posted: 2018-04-10
Enrollment: 25
Sex: ALL
Minimum age (years): 3
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * Confirmed LGMD2E diagnosis by genetic testing or
* Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types

Brief summary: This study is to recruit and establish baseline measurements for potential subjects that may be eligible for a gene therapy trial. Specifically, this trial is recruiting individuals who are suspected or have been confirmed to have Limb Girdle Muscular Dystrophy type 2E (LGMD2E).

Detailed description: This is a longitudinal observational study. It is a 24-month study with the possibility of extending the data time points. Visits will occur monthly. However, at the discretion of the PI, subjects may not be required to return monthly. These subjects may return at intervals ranging from 2 months to a max of 6 months apart.

In the situation that the subjects would fall out of the inclusion criteria or not be eligible for the LGMD2E gene therapy trial, they will be given the opportunity to roll over into the Natural History for LGMD (IRB17-01086). If a subject is invited to screen for the gene therapy trial they will discontinue this trial. By being in this study, it is not a guarantee that subjects will be invited to screen for the LGMD2E gene therapy trial.

Eligibility criteria: Inclusion Criteria:

* Age 3-15 inclusive
* Males or females of any ethnic group
* SGCB DNA gene mutations at both alleles or suspected to have LGMD2E based on family and medical history. If suspected, genetic testing will be performed to confirm diagnosis.
* Weakness demonstrated based on history of difficulty running, jumping and climbing stairs
* Ability to complete 100MW timed test within 30-90% predicted
* Perform assessments to the best of their ability with reliable results as deemed by the evaluator.
* Ability to attend scheduled appointments
* Ability to provide informed consent (or assent for ages 9-15)

Exclusion Criteria:

* Confirmed diagnosis of neuromuscular disorder other than LGMD2E
* Has a medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the subject's ability to comply with the protocol required testing or procedures or compromise the subject's wellbeing, safety, or clinical interpretability
* Subjects with AAVrh74 binding antibody titers \> 1:400 as determined by ELISA immunoassay. If endpoint titer is positive at screening, testing may be repeated in 1 month. Antibody testing will be performed on a separate study (IRB17-01101).
* Diagnosis of (or ongoing treatment for) an autoimmune disease

Primary outcomes:
measure: Baseline Measurements
timeFrame: 2 years
Secondary outcomes:
measure: Disease Progression
timeFrame: 2 years
measure: Registry
timeFrame: 2 years
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
affiliation: Nationwide Children's Hospital
name: Jerry R Mendell, M.D.
role: PRINCIPAL_INVESTIGATOR
References: